ViCentra is closing its UK operations for the time being due to current supply issues. Two years ago ViCentra withdrew the product from the UK market. Meanwhile, the company has started its first users in France, where Kaleido is now being used as part of an early-stage launch of DBGL1, an artificial insulin delivery (AID) solution in partnership with French company, Diabeloop.
Frans Cromme CEO for ViCentra explains, “Since we remain a small organisation which is in the process of scaling up production, it does means that supplies are still limited, to such an extent that we need to concentrate all our efforts on these two existing markets to ensure that we can serve them optimally.
“This subsequently means that we have also taken the difficult decision not to go to any other of the European markets for the time being, including the UK, until we are satisfied that we can guarantee a sufficient supply of goods, which for the UK could take us until 2024 – 2025.
“Consequently, we need to bring closure to all UK operations for the foreseeable future for which we sincerely apologise. Not only is this a huge disappointment for us at ViCentra, but also to those that have been waiting very patiently for our return with Kaleido. Whilst we recognise the importance of the UK market, we also want to act responsibly.
“We hope that you understand our challenging predicament and want to thank you for continued support and patience.”
